{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:01:13Z","timestamp":1791266473518,"version":"4.1.0"},"reference-count":74,"publisher":"SAGE Publications","issue":"s2","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:p>For decades the greatest goal of Parkinson\u2019s disease (PD) research has often been distilled to the discovery of treatments that prevent the disease or its progression. However, until recently only the latter has been realistically pursued through randomized clinical trials of candidate disease-modifying therapy (DMT) conducted on individuals after they received traditional clinical diagnosis of PD (i.e., tertiary prevention trials). Now, in light of major advances in our understanding of the prodromal stages of PD, as well as its genetics and biomarkers, the first secondary prevention trials for PD are beginning. In this review, we take stock of DMT trials to date, summarize the breakthroughs that allow the identification of cohorts at high risk of developing a traditional diagnosis of PD, and describe key design elements of secondary prevention trials and how they depend on the prodromal stage being targeted. These elements address whom to enroll, what interventions to test, and how to measure secondary prevention (i.e., slowed progression during the prodromal stages of PD). Although these design strategies, along with the biological definition, subtype classification, and staging of the disease are evolving, all are driven by continued progress in the underlying science and integrated by a broad motivated community of stakeholders. While considerable methodological challenges remain, opportunities to move clinical trials of DMT to earlier points in the disease process than ever before have begun to unfold, and the prospects for PD prevention are nowtangible.<\/jats:p>","DOI":"10.3233\/jpd-240164","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T10:35:53Z","timestamp":1726828553000},"page":"S381-S393","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Designing the First Trials for Parkinson\u2019s Prevention"],"prefix":"10.1177","volume":"14","author":[{"given":"Grace F.","family":"Crotty","sequence":"first","affiliation":[{"name":"Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Present address: Department of Neurology, Cork University Hospital, Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Ayer","sequence":"additional","affiliation":[{"name":"Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[{"name":"Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27063"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30230-7"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0863"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0058-0"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-181474"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.981249"},{"key":"ref007","unstructured":"LiuJ. A clinical study of the efficacy of idebenone in the treatment of iRBD into synucleinopathies. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT04534023 (2023, accessed 30 July 2024)."},{"key":"ref008","unstructured":"DarweeshS. Slow-SPEED-NL: Slowing Parkinson\u2019s Early Through Exercise Dosage-Netherlands (Slow-SPEED-NL). ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT06193252 (2024, accessed 30 July 2024)."},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200238"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/114.5.2283"},{"key":"ref011","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease.\n                      N Engl J Med\n                      1993; 328: 176\u2013183.","DOI":"10.1056\/NEJM199301213280305"},{"key":"ref012","unstructured":"FahnS. Timing of Levodopa Treatment in Parkinson\u2019s Disease. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT00004733 (2005, accessed 30 July 2024)."},{"key":"ref013","unstructured":"Parkinson Study Group. Safety and Efficacy Study of CEP-1347 in theTreatment of Parkinson\u2019s Disease. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT00040404 (2012, accessed 30 July 2024)."},{"key":"ref014","unstructured":"WeissY. A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson\u2019s Disease (ADAGIO). ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT00256204 (2012, accessed 30 July 2024)."},{"key":"ref015","unstructured":"BealF, OakesD, ShoulsonI. Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3). ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT00740714 (2013, accessed 31 July 2024)."},{"key":"ref016","unstructured":"SimuniT, HollowayR. Efficacy of Isradipine in Early Parkinson Disease. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT02168842 (2020, accessed 31 July 2024)."},{"key":"ref017","unstructured":"SchwarzschildMA, AscherioA, OakesD, MacklinEA. Study of Urate Elevation in Parkinson\u2019s Disease, Phase 3 (SURE-PD3). ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT02642393 (2020, accessed 31 July 2024)."},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.120"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-230436"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27802"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26898"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305420"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27059"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.971252"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51738"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.17504\/protocols.io.n92ldmw6ol5b\/v2"},{"key":"ref027","unstructured":"SimuniT, MarekK, et al. P2P Master Protocol Synopsis & Schedule of Activities, https:\/\/www.ppmiinfo.org\/sites\/default\/files\/docs\/P2P%20Master%20Protocol%20Synopsis-SOA_12July2022-DRAFT.pdf. (2022, accessed 30 July 2024)."},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51753"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16041"},{"key":"ref031","first-page":"1298","volume":"331","author":"Gibbons CH","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac115"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200793"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02358-9"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1684-z"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00473-5"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00405-2"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1557"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212935"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.772"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200235"},{"key":"ref042","author":"Simuni T","journal-title":"Zenodo"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00960-0"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200113"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106740"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00283-1"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03355-8"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28921"},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27505"},{"key":"ref050","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030914"},{"key":"ref051","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.05.002"},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0398-3"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2734"},{"key":"ref054","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001451"},{"key":"ref055","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2277"},{"key":"ref056","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29343"},{"key":"ref057","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31815a3f03"},{"key":"ref058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.02.032"},{"key":"ref059","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4611"},{"key":"ref060","doi-asserted-by":"publisher","DOI":"10.4081\/mrm.2020.511"},{"key":"ref061","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf3934"},{"key":"ref062","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101670"},{"key":"ref063","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22630"},{"key":"ref064","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323"},{"key":"ref065","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993"},{"key":"ref066","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00404-0"},{"key":"ref067","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29683"},{"key":"ref068","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.2c08326"},{"key":"ref069","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02663-0"},{"key":"ref070","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0985"},{"key":"ref071","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200897"},{"key":"ref072","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25548"},{"key":"ref073","first-page":"2449","volume":"28","author":"O\u2019Leary K","year":"2022","journal-title":"Nat Med"},{"key":"ref074","unstructured":"ZhangB. Efficacy and Safety of Rasagiline in Prodromal Parkinson\u2019s Disease. ClinicalTrials.gov, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05611372. Last updated November 10, 2022, accessed 14 April 2024)."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-240164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-240164","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-240164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:53:52Z","timestamp":1777611232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-240164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":74,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2024,10,1]]}},"alternative-id":["10.3233\/JPD-240164"],"URL":"https:\/\/doi.org\/10.3233\/jpd-240164","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}